Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 396,512,832
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,075 M
  • EBITDA $ 23,461 M
  • 60-Month Beta 0.35
  • Price/Sales 6.61
  • Price/Cash Flow 15.32
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 26.94% (-0.82%)
  • Historical Volatility 25.91%
  • IV Percentile 56%
  • IV Rank 25.85%
  • IV High 51.27% on 04/08/25
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 7) 6.26 (2.78%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 6,408
  • Volume Avg (30-Day) 13,832
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 244,733
  • Open Int (30-Day) 219,664
  • Expected Range 218.84 to 231.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.01
  • Number of Estimates 9
  • High Estimate 3.17
  • Low Estimate 2.97
  • Prior Year 2.46
  • Growth Rate Est. (year over year) +22.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
204.27 +10.59%
on 02/04/26
235.25 -3.97%
on 02/17/26
+11.87 (+5.55%)
since 01/20/26
3-Month
204.27 +10.59%
on 02/04/26
238.01 -5.08%
on 11/21/25
-3.54 (-1.54%)
since 11/20/25
52-Week
164.39 +37.42%
on 04/09/25
244.81 -7.72%
on 10/01/25
+25.03 (+12.46%)
since 02/20/25

Most Recent Stories

More News
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

NORTH CHICAGO, Ill. , Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for...

ABBV : 225.87 (+0.68%)
AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill. , Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. 

ABBV : 225.87 (+0.68%)
1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

JPM : 310.23 (+0.71%)
ORCL : 148.55 (-5.10%)
ABBV : 225.87 (+0.68%)
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

ABBV : 225.87 (+0.68%)
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

HELP : 7.00 (+1.45%)
AZN : 204.80 (-0.80%)
JNJ : 243.53 (-1.37%)
HELP.NE : 9.6500 (+1.58%)
ABBV : 225.87 (+0.68%)
TAK : 18.62 (-0.21%)
3 Market-Beating Stocks to Research Further

3 Market-Beating Stocks to Research Further

CCB : 83.02 (-1.13%)
BX : 122.01 (-2.98%)
ABBV : 225.87 (+0.68%)
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

ABT : 112.12 (-0.06%)
ABBV : 225.87 (+0.68%)
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

ABBV : 225.87 (+0.68%)
AbbVie: Q4 Earnings Snapshot

AbbVie: Q4 Earnings Snapshot

ABBV : 225.87 (+0.68%)
AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

ABBV : 225.87 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 234.49
2nd Resistance Point 231.93
1st Resistance Point 228.14
Last Price 225.87
1st Support Level 221.79
2nd Support Level 219.23
3rd Support Level 215.44

See More

52-Week High 244.81
Last Price 225.87
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar